by Hanna | Feb 7, 2024 | Blog Post
Life sciences companies of all sizes face extended time and cost pressures as they work to bring new medicines to patients, as the average cost of research and development (R&D) can exceed $2.8 billion, and it can take more than 10-15 years to bring a new therapy...
by Hanna | Feb 1, 2024 | Issue Brief
Click here to download and view the backgrounder.
by Hanna | Jan 30, 2024 | Blog Post
The Hart-Scott-Rodino (HSR) Act requires companies to report information to the Federal Trade Commission (FTC) and Department of Justice (DOJ) before a planned merger or acquisition (M&A). Under the HSR Act, the agencies enforce premerger reporting requirements...
by Hanna | Jan 10, 2024 | Blog Post, PULSE Partner
PULSE had a conversation with Joan Koerber-Walker, president and CEO of AZBio, which recently celebrated 20 years of supporting the growth of Arizona’s life science industry. Joan, who has led AZBio since 2011, has a vested interest in making Arizona a place where...
by Hanna | Jan 3, 2024 | Blog Post
Thousands of life sciences companies from across the U.S. compete every day to bring the next generation of treatments and cures to market. Within this ecosystem, pharmaceutical manufacturers play a key role in developing new therapies and cures. By mobilizing their...
by Hanna | Dec 18, 2023 | Press Release
Latest guidance could pose unintended consequences for life science ecosystem, pro-innovation M&A Washington, D.C. – In response to the latest merger guidelines released today by the Federal Trade Commission (FTC) and Department of Justice (DOJ), the Partnership...
by Hanna | Dec 13, 2023 | Blog Post, PULSE Partner
Ohio has had incredible success in the life sciences in recent years. The first-ever novel gene therapy brain infusion for Parkinson’s disease was developed here, along with the first-ever gene therapy treatment for Duchenne’s muscular dystrophy. Add state-of-the-art...
by Hanna | Dec 12, 2023 | Blog Post
To view the full event recording, click here. Across the life sciences industry, companies engage in a constant “relay race” to bring new and groundbreaking treatments to market. The critical partnerships and “hand-offs” between companies of all sizes are core...
by Hanna | Nov 28, 2023 | Blog Post
For nearly four decades, policymakers have prioritized bipartisan policies that incentivize investment in groundbreaking medical research – aiming to make new innovations accessible for millions of Americans. As a result, the legislative foundation fueling life...
by Hanna | Nov 13, 2023 | Blog Post
Over the past several decades, the U.S. life sciences ecosystem has emerged as a global leader in innovation with more than 2,300 biopharmaceutical companies spanning every state. Pro-innovation mergers and acquisitions (M&A) have been a critical component of the...